阻止IL-6信号传递通过SLC39A5介导的抑制葡萄糖分泌改善葡萄糖耐受性
Wenli Chen1, Weiyi Cui1, Jianhong Wu2
1Institute of Molecular Medicine, College of Future Technology, Peking University, Beijing 100871, China; Beijing Key Laboratory of Cardiometabolic Molecular Medicine, Peking University, Beijing 100871, China.
Metabolism: clinical and experimental
|June 28, 2023
概括
介质素-6 (IL-6) 通过降低载体SLC39A5.5.5的调节,驱动2型糖尿病的高葡萄糖血症. 准这种IL-6/葡萄糖素通路为糖尿病提供了一种新的治疗策略.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 代谢疾病 代谢疾病
背景情况:
- 肥胖和2型糖尿病 (T2D) 与高胰岛素血症,高葡萄糖血症和轻度炎症有关.
- 胰岛素抵抗和炎症之间的相互作用已经确立,但高葡萄糖血症在糖尿病期间炎症中的作用尚不清楚.
- 这项研究调查了促炎性细胞因子介质素-6 (IL-6) 如何影响葡萄糖分泌.
研究的目的:
- 探索介质素-6 (IL-6) 在葡萄糖分泌中的调节作用.
- 阐明连接IL-6,葡萄糖和2型糖尿病 (T2D) 的分子机制.
- 评估针对IL-6/葡萄糖素轴的治疗潜力.
主要方法:
- 在 rhesus和人类中分析了IL-6,葡萄糖和胰岛素之间的相关性.
- 在肥胖/T2D rhesus和评估葡萄糖耐受性中阻断了tocilizumab的IL-6信号传递.
- 测量了孤立细胞中的葡萄糖分泌,并确定SLC39A5是IL-6效应的调解者.
主要成果:
- 血IL-6与两种物种的血葡萄糖素水平正相关.
- 托西利祖马布治疗降低了葡萄糖,血糖和HbA1c,改善了子的葡萄糖耐受性.
- 通过通过STAT3激活降低SLC39A5的调节,IL-6增加了葡萄糖分泌,减少了和损害了道活性.
结论:
- 通过降低载体SLC39A5.5的调节,IL-6促进高葡萄糖血症.
- 这揭示了T2D病变的新机制,并突出了IL-6的作用.
- 准IL-6/葡萄糖素通路为T2D提供了潜在的治疗策略.
相关概念视频
Hormones Regulating Blood Glucose
3.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.6K
Glucagon-like Receptor Agonists
366
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
366
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
210
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
210
Insulin: The Receptor and Signaling Pathways
1.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K
Hypoglycemia and Glucagon
306
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306


